23rd World Congress on Cancer and Diagnostics: Fighting Cancer Is Our Goal

Are you ready to be part of a global movement to advance cancer research and treatment? This is your chance to connect with leading experts, healthcare professionals, and researchers from around the world.Conference Series is delighted to welcome you to attend the 23rd World Congress on Cancer and Diagnostics scheduled in Toronto, Canada on…

BySenior EditorJuly 25, 2023

THOUGHTSPOT

FDA Launches a Pilot Program to Regulate the Safety Standards Associated with In vitro Diagnostic Tests to Identify Cancer Biomarkers

In a landmark decision, FDA on June 20th, 2023 launched a new pilot program to mitigate the risks involved with certain Laboratory Developed Tests (LDTs) used to develop certain oncology products. It is an important initiative by FDA to address the safety standards associated with unregulated or poorly performing in vitro diagnostic tests. With an…

BySaurabh ChaubeyJune 22, 2023

VIEWPOINTS

Matthew Robinson, CTO, Immunome Shares Insights on Strategic Collaboration with AbbVie to Identify Multiple Novel Oncology Targets

Shots:Matthew spoke about Immunome’s collaboration and option agreement with AbbVie for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery EngineHe also talked about how the partnership with AbbVie can support Immunome’s strategy to maximize the new drug discovery potential of its Discovery Engine…

BySenior EditorMay 8, 2023

EVENTS

Exclusive Coverage: Global PHT Expo & Summit 2023

The 15th and 16th of February saw the Global PHT Expo & Summit taking place at the Hyatt Centric in New Delhi, India.Through Global PHT Summit, it was for the first time that the pharma, healthcare, and technology veterans, pioneers, and professionals converged on the same platform to impart their knowledge on the best & futuristic PHT practices. The theme of the event…

BySenior EditorFebruary 27, 2023

INSIGHTS+

Top Performing Drug of 2021 – Opdivo (December Edition)

Active Ingredient: Nivolumab Strength: 40 mg/4 mL, 100 mg/10 mL, & 240 mg/24 mL solution in a single-dose vial Dosage Form: Injection Mechanism of Action: Programmed cell death-1 receptor antagonists (PD-1) First Approval: US (22 Dec 2014), EU (19 Jun 2015)  Revenue Analysis of OpdivoBMS’ Opdivo gives tough competition to other drugs in the…

BySenior EditorDecember 22, 2022

VIEWPOINTS

PharmaShots Interview: Purnanand Sarma, CEO of Immunome, Shares Insights on R&D Update IL-38 Targeting Antibody Treatment for Cancer

Shots: Purnanand spoke about the preclinical results of lead candidate in oncology and how its identifies IL-38 as a target to treat cancerPurnanand also talked about Immunome’s collaboration with Fox Chase Cancer Center for the further development of its prime productThe interview gives a understanding of Immunome’s goal of developing therapeutics to treat…

BySenior EditorAugust 2, 2022

TOP 20

Top 10 Oncology Companies By 2018 Revenue

The Pharma companies focusing on oncology has been emerging in market with greater needs of people suffering from Cancer. The sales of oncology drugs gradually increasing with diseases. The top oncology companies are now developing more advanced- effective- and tolerable drugs to improve treatment outcomes and the patient experience. Roche proved to be on top…

ByPrince GiriMay 31, 2019